Yahoo Finance • last month
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equival... Full story
Yahoo Finance • last month
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $132.00 price target on Disc Medicine (NASDAQ:IRON) on Wednesday. The company, currently trading at $58.18 with a market capitalization of $2 billion, has seen its stoc... Full story
Yahoo Finance • last month
Director Kevin Bitterman of Disc Medicine, Inc. (NASDAQ:IRON) sold a total of 32,174 shares of common stock on August 13 and 14, 2025. The sales, executed under a prearranged Rule 10b5-1 trading plan, totaled $1.96 million. The biotech com... Full story
Yahoo Finance • 2 months ago
Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (NASDAQ:IRON), sold 2,031 shares of common stock on July 17, 2025, at a price of $59.00, totaling $119,829. The transaction occurred near the stock’s current trading price of... Full story
Yahoo Finance • 3 months ago
[gold bars on brown background] Sanlad/iStock via Getty Images Gold prices (XAUUSD:CUR [https://seekingalpha.com/symbol/XAUUSD:CUR]) edged higher on Tuesday as concerns over the impact of US tariffs boosted the metal’s safe-haven appeal,... Full story
Yahoo Finance • 3 months ago
Disc Medicine, Inc. (NASDAQ:IRON) Chief Executive Officer John D Quisel, sold 5,200 shares of common stock on July 3, 2025, at prices ranging from $55.00 to $55.26, for a total value of $286,454. The transaction occurred with the stock tra... Full story
Yahoo Finance • 3 months ago
[Iron pipe centrifugal pipe casting machine at the foundry] Vladimir Zapletin/iStock via Getty Images Vietnam’s Ministry of Industry and Trade has imposed five-year anti-dumping duties on certain hot-rolled steel imports from China, effec... Full story
Yahoo Finance • 3 months ago
Investing.com - H.C. Wainwright has reiterated its Buy rating and $118.00 price target on Disc Medicine (NASDAQ:IRON), maintaining its positive outlook on the biopharmaceutical company. Currently trading at $53.17, the stock has shown stro... Full story
Yahoo Finance • 4 months ago
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-09... Full story
Yahoo Finance • 4 months ago
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from... Full story
Yahoo Finance • 7 months ago
Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive update from Phase 1b trial of... Full story
Yahoo Finance • 8 months ago
WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story
Yahoo Finance • 8 months ago
WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story
Yahoo Finance • 8 months ago
Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpoint Planning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results f... Full story
Yahoo Finance • 8 months ago
WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering fro... Full story
Yahoo Finance • 8 months ago
WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering fro... Full story
Yahoo Finance • 2 years ago
In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks. European financial markets e... Full story
Yahoo Finance • 2 years ago
WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering fro... Full story
Yahoo Finance • 2 years ago
Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include adolescentsData from all adult patients in BEACON to be presented in an oral presentation at the 65th America... Full story
Yahoo Finance • 2 years ago
Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP)Oral presentation at ASH meeting of updated interim data from BEACON, including a preliminary analysis of the precedented pi... Full story